Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexrazoxane for Cardioprotection in Blood Cancers Treated With Chemotherapy
NCT03589729Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2018
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dexrazoxane in Cardiotoxicity, sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Percentage of patients experiencing a decrease in left ventricular ejection fraction (LVEF) at 6 months. Started Sep 2018; status: recruiting.
02
Drugs
dexrazoxane
03
Conditions
Cardiotoxicity
Beyond the preview
Go deeper on NCT03589729.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03589729.